Literature DB >> 2157773

Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis.

H W Murray1.   

Abstract

In experimental visceral leishmaniasis, intermittently administered interferon-gamma (IFN-gamma) induces antileishmanial activity, which is primarily microbistatic. To determine if the efficacy of IFN-gamma immunotherapy could be enhanced by continuous delivery, Leishmania donovani-infected mice were treated using a subcutaneous osmotic pump. Once-daily intraperitoneal injections of 10(5) or 10(6) units of IFN-gamma inhibited the replication of L. donovani within liver macrophages but overall did not reduce liver parasite burdens. In contrast, a comparable dose of IFN-gamma (2.4 x 10(5) units/day) administered continuously induced an enhanced effect and reduced liver burdens by almost 50%. Although pump delivery did not similarly increase the efficacy of antimony chemotherapy in infected mice, continuous treatment with IFN-gamma plus antimony produced an additive antileishmanial effect. These results suggest that continuous infusions of macrophage-activating lymphokines such as IFN-gamma (used alone or in combination with chemotherapy) may be required to optimize in vivo antimicrobial effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157773     DOI: 10.1093/infdis/161.5.992

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Immunopotentiation of bovine herpes virus subunit vaccination by interleukin-2.

Authors:  H P Hughes; M Campos; D L Godson; S Van Drunen Littel-Van den Hurk; L McDougall; N Rapin; T Zamb; L A Babiuk
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

3.  PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice.

Authors:  Christine M Fam; Stephen P Eisenberg; Sharon J Carlson; Elizabeth A Chlipala; George N Cox; Mary S Rosendahl
Journal:  J Interferon Cytokine Res       Date:  2014-05-19       Impact factor: 2.607

4.  Modulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Cristina M Lu; Elaine B Brooks; Richard E Fichtl; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

5.  Effector role of blood monocytes in experimental visceral leishmaniasis.

Authors:  J S Cervia; H Rosen; H W Murray
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

6.  In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.

Authors:  W L Roberts; J D Berman; P M Rainey
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  Molecular chimerization of Pasteurella haemolytica leukotoxin to interleukin-2: effects on cytokine and antigen function.

Authors:  H P Hughes; M Campos; A A Potter; L A Babiuk
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.

Authors:  H W Murray; J Hariprashad; D F McDermott; M Y Stoeckle
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Gamma interferon suppresses acute and chronic Trypanosoma cruzi infection in cyclosporin-treated mice.

Authors:  R McCabe; S Meagher; B Mullins
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

10.  Virulence attenuation of a UDP-galactose/N-acetylglucosamine beta1,4 galactosyltransferase expressing Leishmania donovani promastigote.

Authors:  S K Bhaumik; M Singh; R Basu; S Bhaumik; K Roychoudhury; K Naskar; S Roy; T De
Journal:  Glycoconj J       Date:  2008-01-16       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.